Payment overview · 2025
General Payments
$79.50
4 reported records · 4 companies
Healthcare provider profile · identity verified
Luis S Veras, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · MIAMI, FL · NPI 1215013560
Verified facts
What the public records show
CMS Open Payments records show Luis S Veras, MD received $79.50 in general payments during 2025 across 4 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.90 | 28.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.85 | 27.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.98 | 25.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.77 | 18.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.50 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 80 |
| Omeprazole | Omeprazole | 323 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 87 |
| Gabapentin | Gabapentin | 271 | 75 |
| Losartan Potassium | Losartan Potassium | 264 | 77 |
| Alprazolam | Alprazolam | 250 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 66 |
| Metformin Hcl | Metformin Hcl | 204 | 57 |
| Valsartan | Valsartan | 204 | 51 |
| Donepezil Hcl | Donepezil Hcl | 195 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 59 |
| Famotidine | Famotidine | 188 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 52 |
| Lisinopril | Lisinopril | 161 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 48 |
| Ibuprofen | Ibuprofen | 146 | 43 |
| Furosemide | Furosemide | 145 | 46 |
| Simvastatin | Simvastatin | 145 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 40 |
| Mirtazapine | Mirtazapine | 140 | 40 |
| Temazepam | Temazepam | 136 | 29 |
| Alendronate Sodium | Alendronate Sodium | 125 | 38 |
| Eliquis | Apixaban | 117 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 107 | 59 |
| Nifedipine Er | Nifedipine | 104 | 28 |
| Montelukast Sodium | Montelukast Sodium | 103 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 101 | 43 |
| Carvedilol | Carvedilol | 95 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 24 |
| Azithromycin | Azithromycin | 86 | 74 |
| Glipizide | Glipizide | 86 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 83 | 24 |
| Folic Acid | Folic Acid | 83 | 25 |
| Linzess | Linaclotide | 82 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 22 |
| Synthroid | Levothyroxine Sodium | 72 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 30 |
| Ketoconazole | Ketoconazole | 66 | 18 |
| Lorazepam | Lorazepam | 66 | 12 |
| Meloxicam | Meloxicam | 66 | 23 |
| Trazodone Hcl | Trazodone Hcl | 64 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Ciclopirox | Ciclopirox | 60 | 22 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Finasteride | Finasteride | 57 | 15 |
| Meclizine Hcl | Meclizine Hcl | 56 | 24 |
| Memantine Hcl | Memantine Hcl | 56 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | 17 |
| Potassium Chloride | Potassium Chloride | 51 | 16 |
| Clonazepam | Clonazepam | 48 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 47 | 15 |
| Glipizide Er | Glipizide | 47 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Ozempic | Semaglutide | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 45 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 18 |
| Xarelto | Rivaroxaban | 42 | 15 |
| Myrbetriq | Mirabegron | 40 | 14 |
| Atenolol | Atenolol | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 34 | 11 |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Prednisone | Prednisone | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Restasis | Cyclosporine | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Ssd | Silver Sulfadiazine | 28 | 11 |
| Benzonatate | Benzonatate | 27 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Prolia | Denosumab | 22 | 12 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Lidocaine | Lidocaine | 19 | suppressed |
| Ofloxacin | Ofloxacin | 19 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | 11 |
| Repaglinide | Repaglinide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Apidra Solostar | Insulin Glulisine | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pregabalin | Pregabalin | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Danazol | Danazol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.50 · 4 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | MOUNJARO, The Cologuard Plus Collection Kit, VOQUEZNA, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error